scholarly journals Prescription opioid injection among young people who inject drugs in New York City: a mixed-methods description and associations with hepatitis C virus infection and overdose

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Pedro Mateu-Gelabert ◽  
Honoria Guarino ◽  
Jon E. Zibbell ◽  
Jennifer Teubl ◽  
Chunki Fong ◽  
...  

Abstract Aim Evidence is emerging that prescription opioid (PO) injection is associated with increased health risks. This mixed-methods study compares the mechanics of PO and heroin injection and examines the demographic and drug-related correlates of lifetime PO injection in a sample of young people who inject drugs (PWID) in New York City (NYC). Methods Qualitative analysis of 46 semi-structured interviews with young adult opioid users ages 18–32. Interview segments describing PO injection were analyzed for common themes. Quantitative analysis of structured interviews with 539 young adult opioid users ages 18–29 recruited via respondent-driven sampling (RDS). Analyses are based on the subsample of 353 participants (65%) who reported having ever injected drugs. All variables were assessed via self-report, except hepatitis C virus status, which was established via rapid antibody testing. Results Participants described injecting POs and reported that preparing abuse-deterrent pills for injection is especially cumbersome, requiring extended manipulation and large amounts of water. Injecting POs, in contrast to injecting heroin, requires repeated injections per injection episode. Among RDS-recruited participants, the majority of injectors reported injecting POs, sporadically (33%) or regularly (26%), but often infrequently (≤ 7 days/month). In separate multivariable analyses controlling for syringe- and cooker-sharing, ever injecting POs was a significant predictor of testing HCV antibody-positive (AOR = 2.97) and lifetime experience of non-fatal overdose (AOR = 2.51). Ever injecting POs was independently associated with lifetime homelessness (AOR = 2.93) and having grown up in a middle-income ($51,000–100,000/year vs. ≤ $50,000/year; AOR = 1.86) or a high-income household (> $100,000/year vs. ≤ $50,000/year; AOR = 2.54). Conclusions Even in an urban environment like NYC with widespread heroin access, most young PWID have injected POs, although less frequently than heroin. PO injection involves practices that are known to increase risk for blood-borne viral infection (e.g., repeated injections) and predicted testing HCV-positive, as well as overdose. PO injection may also serve as a marker for a subgroup of PWID at elevated risk for multiple drug use-related comorbidities. Programs that provide prevention services to PWID need to tailor harm reduction measures and messaging to the specific practices and harms associated with the injection of POs.

PLoS ONE ◽  
2017 ◽  
Vol 12 (5) ◽  
pp. e0177341 ◽  
Author(s):  
Benjamin Eckhardt ◽  
Emily R. Winkelstein ◽  
Marla A. Shu ◽  
Michael R. Carden ◽  
Courtney McKnight ◽  
...  

2009 ◽  
Vol 101 (1-2) ◽  
pp. 88-91 ◽  
Author(s):  
Don C. Des Jarlais ◽  
Kamyar Arasteh ◽  
Courtney McKnight ◽  
Holly Hagan ◽  
David Perlman ◽  
...  

2020 ◽  
Author(s):  
Shashi N. Kapadia ◽  
Caroline Katzman ◽  
Chunki Fong ◽  
Benjamin J. Eckhardt ◽  
Honoria Guarino ◽  
...  

2020 ◽  
Vol 222 (Supplement_5) ◽  
pp. S322-S334
Author(s):  
Ashly E Jordan ◽  
Charles M Cleland ◽  
Katarzyna Wyka ◽  
Bruce R Schackman ◽  
David C Perlman ◽  
...  

Abstract Background Hepatitis C virus (HCV) incidence has increased in the worsening opioid epidemic. We examined the HCV preventive efficacy of medication-assisted treatment (MAT), and geographic variation in HCV community viral load (CVL) and its association with HCV incidence. Methods HCV incidence was directly measured in an open cohort of patients in a MAT program in New York City between 1 January 2013 and 31 December 2016. Area-level HCV CVL was calculated. Associations of individual-level factors, and of HCV CVL, with HCV incidence were examined in separate analyses. Results Among 8352 patients, HCV prevalence was 48.7%. Among 2535 patients seronegative at first antibody test, HCV incidence was 2.25/100 person-years of observation (PYO). Incidence was 6.70/100 PYO among those reporting main drug use by injection. Female gender, drug injection, and lower MAT retention were significantly associated with higher incidence rate ratios. Female gender, drug injection, and methadone doses <60 mg were independently associated with shorter time to HCV seroconversion. HCV CVLs varied significantly by geographic area. Conclusions HCV incidence was higher among those with lower MAT retention and was lower among those receiving higher methadone doses, suggesting the need to ensure high MAT retention, adequate doses, and increased HCV prevention and treatment engagement. HCV CVLs vary geographically and merit further study as predictors of HCV incidence.


2019 ◽  
Vol 198 ◽  
pp. 133-135 ◽  
Author(s):  
Meghan D. Morris ◽  
Ali Mirzazadeh ◽  
Jennifer L. Evans ◽  
Alya Briceno ◽  
Phillip Coffin ◽  
...  

2017 ◽  
Vol 46 ◽  
pp. 17-27 ◽  
Author(s):  
Pedro Mateu-Gelabert ◽  
Lauren Jessell ◽  
Elizabeth Goodbody ◽  
Dongah Kim ◽  
Krista Gile ◽  
...  

2016 ◽  
Vol 131 (3) ◽  
pp. 430-437 ◽  
Author(s):  
Andrea King ◽  
Katherine Bornschlegel ◽  
Nirah Johnson ◽  
Eric Rude ◽  
Fabienne Laraque

Sign in / Sign up

Export Citation Format

Share Document